| Year |
Citation |
Score |
| 2016 |
Patel A, Sharp SY, Hall K, Lewis W, Stevens MF, Workman P, Moody CJ. Fused imidazoles as potential chemical scaffolds for inhibition of heat shock protein 70 and induction of apoptosis. Synthesis and biological evaluation of phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthrolines. Organic & Biomolecular Chemistry. PMID 27035072 DOI: 10.1039/C6Ob00471G |
0.314 |
|
| 2015 |
Zhang J, Hummersone M, Matthews CS, Stevens MF, Bradshaw TD. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death. Oncology. 88: 28-48. PMID 25277441 DOI: 10.1159/000366131 |
0.374 |
|
| 2014 |
Rizzo A, Iachettini S, Zizza P, Cingolani C, Porru M, Artuso S, Stevens M, Hummersone M, Biroccio A, Salvati E, Leonetti C. Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities. Journal of Experimental & Clinical Cancer Research : Cr. 33: 81. PMID 25288403 DOI: 10.1186/s13046-014-0081-x |
0.36 |
|
| 2014 |
Schwalbe C, Wells G, Stevens M. Influence of steric crowding on hydrogen bonding in anti-cancer quinols Acta Crystallographica Section a Foundations and Advances. 70: C561-C561. DOI: 10.1107/S2053273314094388 |
0.599 |
|
| 2012 |
Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Current Molecular Pharmacology. 5: 102-14. PMID 22122467 DOI: 10.2174/1874467211205010102 |
0.315 |
|
| 2011 |
Zhang J, Stevens MF, Hummersone M, Madhusudan S, Laughton CA, Bradshaw TD. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair. Oncology. 80: 195-207. PMID 21720182 DOI: 10.1159/000327837 |
0.379 |
|
| 2011 |
König J, Wyllie S, Wells G, Stevens MF, Wyatt PG, Fairlamb AH. Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism. The Journal of Biological Chemistry. 286: 8523-33. PMID 21212280 DOI: 10.1074/Jbc.M110.214833 |
0.625 |
|
| 2010 |
McCarroll AJ, Matthews CS, Wells G, Bradshaw TD, Stevens MF. Synthesis of antitumour (1H-1,2,3-triazol-4-yl)-4-hydroxycyclohexa-2,5-dien-1-ones by copper-catalysed Huisgen cycloadditions. Organic & Biomolecular Chemistry. 8: 2078-84. PMID 20401384 DOI: 10.1039/B920039H |
0.665 |
|
| 2010 |
Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology. 78: 103-14. PMID 20357518 DOI: 10.1159/000306139 |
0.364 |
|
| 2008 |
Kadri H, Matthews CS, Bradshaw TD, Stevens MF, Westwell AD. Synthesis and antitumour evaluation of novel 2-phenylbenzimidazoles. Journal of Enzyme Inhibition and Medicinal Chemistry. 23: 641-7. PMID 18821253 DOI: 10.1080/14756360802205398 |
0.436 |
|
| 2008 |
Aiello S, Wells G, Stone EL, Kadri H, Bazzi R, Bell DR, Stevens MF, Matthews CS, Bradshaw TD, Westwell AD. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). Journal of Medicinal Chemistry. 51: 5135-9. PMID 18666770 DOI: 10.1021/Jm800418Z |
0.707 |
|
| 2008 |
Cheng MK, Modi C, Cookson JC, Hutchinson I, Heald RA, McCarroll AJ, Missailidis S, Tanious F, Wilson WD, Mergny JL, Laughton CA, Stevens MF. Antitumor polycyclic acridines. 20. Search for DNA quadruplex binding selectivity in a series of 8,13-dimethylquino[4,3,2-kl]acridinium salts: telomere-targeted agents. Journal of Medicinal Chemistry. 51: 963-75. PMID 18247546 DOI: 10.1021/Jm070587T |
0.353 |
|
| 2007 |
McCarroll AJ, Bradshaw TD, Westwell AD, Matthews CS, Stevens MF. Quinols as novel therapeutic agents. 7.1 Synthesis of antitumor 4-[1-(arylsulfonyl-1H-indol-2-yl)]-4-hydroxycyclohexa-2,5-dien-1-ones by Sonogashira reactions. Journal of Medicinal Chemistry. 50: 1707-10. PMID 17343370 DOI: 10.1021/Jm061163M |
0.46 |
|
| 2007 |
Jada SR, Subur GS, Matthews C, Hamzah AS, Lajis NH, Saad MS, Stevens MF, Stanslas J. Semisynthesis and in vitro anticancer activities of andrographolide analogues. Phytochemistry. 68: 904-12. PMID 17234223 DOI: 10.1016/J.Phytochem.2006.11.031 |
0.381 |
|
| 2006 |
Lion CJ, Matthews CS, Wells G, Bradshaw TD, Stevens MF, Westwell AD. Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2,5-dienones ('quinols'). Bioorganic & Medicinal Chemistry Letters. 16: 5005-8. PMID 16908135 DOI: 10.1016/J.Bmcl.2006.07.072 |
0.689 |
|
| 2006 |
Vasselin DA, Westwell AD, Matthews CS, Bradshaw TD, Stevens MF. Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzothiazoles. Journal of Medicinal Chemistry. 49: 3973-81. PMID 16789754 DOI: 10.1021/Jm060359J |
0.525 |
|
| 2006 |
Jada SR, Hamzah AS, Lajis NH, Saad MS, Stevens MF, Stanslas J. Semisynthesis and cytotoxic activities of andrographolide analogues. Journal of Enzyme Inhibition and Medicinal Chemistry. 21: 145-55. PMID 16789428 DOI: 10.1080/14756360500499988 |
0.367 |
|
| 2006 |
Chew EH, Matthews CS, Zhang J, McCarroll AJ, Hagen T, Stevens MF, Westwell AD, Bradshaw TD. Antitumor quinols: role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets. Biochemical and Biophysical Research Communications. 346: 242-51. PMID 16756956 DOI: 10.1016/j.bbrc.2006.05.106 |
0.307 |
|
| 2006 |
Mortimer CG, Wells G, Crochard JP, Stone EL, Bradshaw TD, Stevens MF, Westwell AD. Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. Journal of Medicinal Chemistry. 49: 179-85. PMID 16392802 DOI: 10.1021/Jm050942K |
0.724 |
|
| 2006 |
Shah M, Wells G, Bradshaw T, Laughton C, Stevens M, Westwell A. Antitubercular Properties of Substituted Hydroxycyclohexadienones Letters in Drug Design & Discovery. 3: 419-423. DOI: 10.2174/157018006777805486 |
0.617 |
|
| 2005 |
Bradshaw TD, Matthews CS, Cookson J, Chew EH, Shah M, Bailey K, Monks A, Harris E, Westwell AD, Wells G, Laughton CA, Stevens MF. Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Research. 65: 3911-9. PMID 15867391 DOI: 10.1158/0008-5472.Can-04-4141 |
0.672 |
|
| 2005 |
Lion CJ, Matthews CS, Stevens MF, Westwell AD. Synthesis, antitumor evaluation, and apoptosis-inducing activity of hydroxylated (E)-stilbenes. Journal of Medicinal Chemistry. 48: 1292-5. PMID 15715501 DOI: 10.1021/Jm049238E |
0.415 |
|
| 2005 |
Berry JM, Bradshaw TD, Fichtner I, Ren R, Schwalbe CH, Wells G, Chew EH, Stevens MF, Westwell AD. Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents. Journal of Medicinal Chemistry. 48: 639-44. PMID 15658878 DOI: 10.1021/jm040859h |
0.706 |
|
| 2005 |
Mukherjee A, Westwell AD, Bradshaw TD, Stevens MF, Carmichael J, Martin SG. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. British Journal of Cancer. 92: 350-8. PMID 15655539 DOI: 10.1038/sj.bjc.6602338 |
0.341 |
|
| 2004 |
Brantley E, Trapani V, Alley MC, Hose CD, Bradshaw TD, Stevens MF, Sausville EA, Stinson SF. Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 32: 1392-401. PMID 15355884 DOI: 10.1124/Dmd.104.001057 |
0.366 |
|
| 2004 |
Richardson ML, Croughton KA, Matthews CS, Stevens MF. Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims'). Journal of Medicinal Chemistry. 47: 4105-8. PMID 15267250 DOI: 10.1021/Jm040785+ |
0.438 |
|
| 2003 |
Wells G, Berry JM, Bradshaw TD, Burger AM, Seaton A, Wang B, Westwell AD, Stevens MF. 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. Journal of Medicinal Chemistry. 46: 532-41. PMID 12570375 DOI: 10.1021/Jm020984Y |
0.702 |
|
| 2003 |
Hutchinson I, Bradshaw TD, Matthews CS, Stevens MF, Westwell AD. Antitumour benzothiazoles. Part 20: 3'-cyano and 3'-alkynyl-substituted 2-(4'-aminophenyl)benzothiazoles as new potent and selective analogues. Bioorganic & Medicinal Chemistry Letters. 13: 471-4. PMID 12565953 DOI: 10.1016/S0960-894X(02)00930-7 |
0.391 |
|
| 2002 |
Bradshaw TD, Bibby MC, Double JA, Fichtner I, Cooper PA, Alley MC, Donohue S, Stinson SF, Tomaszewjski JE, Sausville EA, Stevens MF. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Molecular Cancer Therapeutics. 1: 239-46. PMID 12467219 |
0.321 |
|
| 2002 |
Arrowsmith J, Jennings SA, Clark AS, Stevens MF. Antitumor imidazotetrazines. 41. Conjugation of the antitumor agents mitozolomide and temozolomide to peptides and lexitropsins bearing DNA major and minor groove-binding structural motifs. Journal of Medicinal Chemistry. 45: 5458-70. PMID 12459014 DOI: 10.1021/Jm020936D |
0.321 |
|
| 2002 |
Bradshaw TD, Chua MS, Browne HL, Trapani V, Sausville EA, Stevens MF. In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. British Journal of Cancer. 86: 1348-54. PMID 11953897 DOI: 10.1038/sj.bjc.6600225 |
0.306 |
|
| 2002 |
Heald RA, Modi C, Cookson JC, Hutchinson I, Laughton CA, Gowan SM, Kelland LR, Stevens MF. Antitumor polycyclic acridines. 8.(1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts. Journal of Medicinal Chemistry. 45: 590-7. PMID 11806711 DOI: 10.1021/Jm011015Q |
0.45 |
|
| 2002 |
Loaiza-Pérez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MF, Bradshaw TD, Sausville EA. Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Molecular Pharmacology. 61: 13-9. PMID 11752201 DOI: 10.1124/Mol.61.1.13 |
0.367 |
|
| 2001 |
Gowan SM, Heald R, Stevens MF, Kelland LR. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Molecular Pharmacology. 60: 981-8. PMID 11641426 DOI: 10.1124/Mol.60.5.981 |
0.403 |
|
| 2001 |
Shi DF, Bradshaw TD, Chua MS, Westwell AD, Stevens MF. Antitumour benzothiazoles. Part 15: The synthesis and physico-chemical properties of 2-(4-aminophenyl)benzothiazole sulfamate salt derivatives. Bioorganic & Medicinal Chemistry Letters. 11: 1093-5. PMID 11327598 DOI: 10.1016/S0960-894X(01)00142-1 |
0.311 |
|
| 2001 |
Hutchinson I, Chua MS, Browne HL, Trapani V, Bradshaw TD, Westwell AD, Stevens MF. Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. Journal of Medicinal Chemistry. 44: 1446-55. PMID 11311068 DOI: 10.1021/Jm001104N |
0.461 |
|
| 2001 |
Bradshaw TD, Stevens MF, Westwell AD. The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds. Current Medicinal Chemistry. 8: 203-10. PMID 11172675 DOI: 10.2174/0929867013373714 |
0.416 |
|
| 2000 |
Bradshaw TD, Chua MS, Orr S, Matthews CS, Stevens MF. Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445). British Journal of Cancer. 83: 270-7. PMID 10901382 DOI: 10.1054/bjoc.2000.1231 |
0.346 |
|
| 2000 |
Stanslas J, Hagan DJ, Ellis MJ, Turner C, Carmichael J, Ward W, Hammonds TR, Stevens MF. Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines. Journal of Medicinal Chemistry. 43: 1563-72. PMID 10780913 DOI: 10.1021/Jm9909490 |
0.449 |
|
| 2000 |
Wells G, Seaton A, Stevens MF. Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents. Journal of Medicinal Chemistry. 43: 1550-62. PMID 10780912 DOI: 10.1021/Jm990947F |
0.688 |
|
| 2000 |
Wells G, Bradshaw TD, Diana P, Seaton A, Shi DF, Westwell AD, Stevens MF. Antitumour benzothiazoles. Part 10: the synthesis and antitumour activity of benzothiazole substituted quinol derivatives. Bioorganic & Medicinal Chemistry Letters. 10: 513-5. PMID 10743960 DOI: 10.1016/S0960-894X(00)00027-5 |
0.688 |
|
| 1999 |
Kashiyama E, Hutchinson I, Chua MS, Stinson SF, Phillips LR, Kaur G, Sausville EA, Bradshaw TD, Westwell AD, Stevens MF. Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles. Journal of Medicinal Chemistry. 42: 4172-84. PMID 10514287 DOI: 10.1021/Jm990104O |
0.441 |
|
| 1999 |
Bostock-Smith CE, Giménez-Arnau E, Missailidis S, Laughton CA, Stevens MF, Searle MS. Molecular recognition between a new pentacyclic acridinium salt and DNA sequences investigated by optical spectroscopic techniques, proton nuclear magnetic resonance spectroscopy, and molecular modeling. Biochemistry. 38: 6723-31. PMID 10346892 DOI: 10.1021/Bi9825807 |
0.376 |
|
| 1999 |
Chua MS, Shi DF, Wrigley S, Bradshaw TD, Hutchinson I, Shaw PN, Barrett DA, Stanley LA, Stevens MF. Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines. Journal of Medicinal Chemistry. 42: 381-92. PMID 9986708 DOI: 10.1021/JM981076X |
0.332 |
|
| 1998 |
Bradshaw TD, Shi DF, Schultz RJ, Paull KD, Kelland L, Wilson A, Garner C, Fiebig HH, Wrigley S, Stevens MF. Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo. British Journal of Cancer. 78: 421-9. PMID 9716022 DOI: 10.1038/bjc.1998.510 |
0.307 |
|
| 1998 |
Bradshaw TD, Wrigley S, Shi DF, Schultz RJ, Paull KD, Stevens MF. 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity. British Journal of Cancer. 77: 745-52. PMID 9514053 DOI: 10.1038/bjc.1998.122 |
0.373 |
|
| 1997 |
Wang Y, Stevens MF, Chan Tm, DiBenedetto D, Ding Zx, Gala D, Hou D, Kugelman M, Leong W, Kuo Sc, Mas JL, Schumacher DP, Shutts BP, Smith L, Zhan ZY, et al. Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide. The Journal of Organic Chemistry. 62: 7288-7294. PMID 11671842 DOI: 10.1021/Jo970802L |
0.396 |
|
| 1997 |
Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Reviews. 23: 35-61. PMID 9189180 DOI: 10.1016/S0305-7372(97)90019-0 |
0.59 |
|
| 1996 |
Shi DF, Bradshaw TD, Wrigley S, McCall CJ, Lelieveld P, Fichtner I, Stevens MF. Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. Journal of Medicinal Chemistry. 39: 3375-84. PMID 8765521 DOI: 10.1021/Jm9600959 |
0.519 |
|
| 1995 |
Clark AS, Deans B, Stevens MF, Tisdale MJ, Wheelhouse RT, Denny BJ, Hartley JA. Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. Journal of Medicinal Chemistry. 38: 1493-504. PMID 7739008 DOI: 10.1021/Jm00009A010 |
0.7 |
|
| 1994 |
Stevens MF, McCall CJ, Lelieveld P, Alexander P, Richter A, Davies DE. Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin. Journal of Medicinal Chemistry. 37: 1689-95. PMID 8201603 DOI: 10.1021/JM00037A020 |
0.323 |
|
| 1994 |
Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 33: 9045-51. PMID 8049205 DOI: 10.1021/Bi00197A003 |
0.655 |
|
| 1992 |
Denny BJ, Ringan NS, Schwalbe CH, Lambert PA, Meek MA, Griffin RJ, Stevens MF. Structural studies on bio-active compounds. 20. Molecular modeling and crystallographic studies on methylbenzoprim, a potent inhibitor of dihydrofolate reductase. Journal of Medicinal Chemistry. 35: 2315-20. PMID 1613754 DOI: 10.1021/Jm00090A023 |
0.337 |
|
| 1990 |
Horspool KR, Stevens MF, Newton CG, Lunt E, Walsh RJ, Pedgrift BL, Baig GU, Lavelle F, Fizames C. Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents. Journal of Medicinal Chemistry. 33: 1393-9. PMID 2329560 DOI: 10.1021/JM00167A018 |
0.313 |
|
| 1989 |
Sansom CE, Schwalbe CH, Lambert PA, Griffin RJ, Stevens MF. Structural studies on bio-active compounds. Part XV. Structure-activity relationships for pyrimethamine and a series of diaminopyrimidine analogues versus bacterial dihydrofolate reductase. Biochimica Et Biophysica Acta. 995: 21-7. PMID 2647153 DOI: 10.1016/0167-4838(89)90228-8 |
0.375 |
|
| 1987 |
Lunt E, Newton CG, Smith C, Stevens GP, Stevens MF, Straw CG, Walsh RJ, Warren PJ, Fizames C, Lavelle F. Antitumor imidazotetrazines. 14. Synthesis and antitumor activity of 6- and 8-substituted imidazo[5,1-d]-1,2,3,5-tetrazinones and 8-substituted pyrazolo[5,1-d]-1,2,3,5-tetrazinones. Journal of Medicinal Chemistry. 30: 357-66. PMID 3806616 DOI: 10.1021/JM00385A018 |
0.306 |
|
| 1984 |
Vaughan K, Tang Y, Llanos G, Horton JK, Simmonds RJ, Hickman JA, Stevens MF. Studies of the mode of action of antitumor triazenes and triazines. 6. 1-Aryl-3-(hydroxymethyl)-3-methyltriazenes: synthesis, chemistry, and antitumor properties. Journal of Medicinal Chemistry. 27: 357-63. PMID 6699881 DOI: 10.1002/Chin.198432250 |
0.355 |
|
| 1984 |
Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, Newton CG. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. Journal of Medicinal Chemistry. 27: 196-201. PMID 6694168 DOI: 10.1002/Chin.198429227 |
0.403 |
|
| 1984 |
Langdon SP, Gescher A, Hickman JA, Stevens MF. The chemosensitivity of a new experimental model--the M5076 reticulum cell sarcoma. European Journal of Cancer & Clinical Oncology. 20: 699-705. PMID 6428895 DOI: 10.1016/0277-5379(84)90019-1 |
0.322 |
|
| 1984 |
Ross D, Langdon SP, Gescher A, Stevens MF. Studies of the mode of action of antitumour triazenes and triazines—V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism Biochemical Pharmacology. 33: 1131-1136. DOI: 10.1016/0006-2952(84)90525-2 |
0.424 |
|
| 1981 |
Gescher A, Hickman JA, Simmonds RJ, Stevens MF, Vaughan K. Studies of the mode of action of antitumour triazenes and triazines-II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenes. Biochemical Pharmacology. 30: 89-93. PMID 7213416 DOI: 10.1016/0006-2952(81)90288-4 |
0.363 |
|
| 1977 |
Gescher A, Stevens MF, Turnbull CP. Triazines and related products. Part 19. 4-Amino-2-[2-(piperid-n-1-ylazo)phenyl]quinazoline and its analogues. Journal of the Chemical Society. Perkin Transactions 1. 2: 107-14. PMID 556733 DOI: 10.1039/P19770000107 |
0.371 |
|
| 1975 |
Bradshaw D, Butchart GA, Hemsworth BA, Stevens MF. Proceedings: Inhibition of cholinesterase activity by two methylacridinium compounds. The Journal of Pharmacy and Pharmacology. 123P. PMID 4156718 DOI: 10.1111/J.2042-7158.1974.Tb10157.X |
0.406 |
|
| Show low-probability matches. |